#Switzerland #ADC Therapeutics #ZYNLONTA #Lausanne #Rituximab

Exciting Clinical Data on ZYNLONTA® and Rituximab for Relapsed/Refractory Follicular Lymphoma

ADC Therapeutics SA, a notable leader in the field of antibody drug conjugates (ADCs), has recently advanced its ongoing commitment to patient care by announcing significant findings from a Phase 2 clinical trial involving its drug, ZYNLONTA® (loncastuximab tesirine-lpyl), combined with Rituximab for patients suffering from relapsed or refractory follicular lymphoma (FL). The data was recently published in The Lancet Haematology and was also highlighted during an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting.

Key Findings of the Trial

The rigorous trial engaged 39 patients with a `median age of 68 years`, most of whom had undergone at least one prior line of treatment. A pivotal endpoint of the study was the complete response rate (CR) as determined by PET/CT imaging at week 12. The results were remarkable:

• - Best Overall Response Rate (ORR): 97.4% among evaluable participants.
• - Complete Response Rate (CR): 76.9% was achieved, showcasing the treatment's efficacy.

After a median follow-up of 15.6 months, patients had a 12-month Progression-Free Survival (PFS) rate of 94.6%, indicating promising long-term benefits.

Safety and Adverse Events

The combination therapy was generally well-tolerated, highlighting the importance of understanding potential side effects in clinical settings. Common treatment-emergent adverse events included:

• - Hyperglycemia: 43.6%
• - Increased alkaline phosphatase: 41%
• - Neutropenia and fatigue: affecting 38.5% of patients

Moreover, the only noteworthy grade 3 or higher adverse events were deemed manageable and included lymphopenia and neutropenia, with no instances of severe (Grade 5) adverse events occurring.

Insights from ADC Therapeutics Team

Dr. Mohamed Zaki, Chief Medical Officer at ADC Therapeutics, expressed enthusiasm regarding the publication, emphasizing the drug's efficacy particularly for patients categorized as high-risk or facing significant disease burden. “These findings reinforce ZYNLONTA’s potential to address unmet needs in the treatment landscape for indolent B-cell lymphomas and contribute to an expanding body of evidence for its efficacy,” stated Dr. Zaki.

Additional Research on ZYNLONTA

Furthermore, ADC presented supplementary findings at ASH regarding ZYNLONTA used as a single agent for marginal zone lymphoma (MZL), revealing an ORR of 91% and CR rates of 70%. These encouraging results bolster ZYNLONTA's status as a serious contender in treating various lymphomas, extending its reach beyond just diffuse large B-cell lymphoma.

Importance of Clinical Trials

The findings underscore the vital role of clinical trials in discovering effective treatments for severe conditions like lymphoma. For researchers, these insights help delineate pathways towards better-targeted therapies tailored for patients with unique profiles and needs.

Looking Ahead

ADC Therapeutics plans to continue its advancements with ZYNLONTA, exploring additional combinations and therapeutic options in broader patient populations. The company is striving to redefine treatment protocols across challenged demographics, aiming for impactful outcomes.

Further details on this investigation, including enrollment criteria and contact for clinical trials, can be found on the official clinical trials website.

As ZYNLONTA enhances its footprint in hematologic malignancies, ADC Therapeutics is positioned at the forefront of innovation in cancer treatment, leveraging its ADC technology to transform patient care.

For further inquiries and information about ADC Therapeutics, you can visit their official website.